Press releases
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
- Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
- Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
- Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
- Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
More ▼
Key statistics
On Wednesday, Actinium Pharmaceuticals Inc (7AY1:BER) closed at 6.95, -23.26% below its 52-week high of 9.05, set on Apr 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.30 |
---|---|
High | 7.30 |
Low | 6.94 |
Bid | -- |
Offer | -- |
Previous close | 7.31 |
Average volume | 867.78 |
---|---|
Shares outstanding | 29.40m |
Free float | 28.76m |
P/E (TTM) | -- |
Market cap | 227.53m USD |
EPS (TTM) | -1.84 USD |
Data delayed at least 15 minutes, as of Apr 17 2024 19:21 BST.
More ▼